Published in

Wiley, British Journal of Haematology, 1(194), p. 140-144, 2021

DOI: 10.1111/bjh.17462

Links

Tools

Export citation

Search in Google Scholar

High risk of relapse with intermediate dose cytarabine for consolidation in young favourable‐risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature

Journal article published in 2021 by Bhaskar C. Kolla ORCID, Nurul A. A. Halim, Qing Cao, Zohar Sachs ORCID, Erica Warlick, Daniel Weisdorf ORCID, Aloysius Y. L. Ho, Wong G. Chuan, Zhentang Lao, Fiona He
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

SummaryFollowing the 2017 European LeukemiaNet (ELN) guidelines, we changed our practice from using high‐dose cytarabine (HIDAC‐3 g/m2 q12h‐D1,3,5) to intermediate‐dose cytarabine (IDAC‐1·5 g/m2 q12h‐D1,3,5/D1–3) for consolidation in young(<60 years) favourable‐risk acute myeloid leukaemia (AML) patients. We assessed the clinical impact of this practice change. Of 80 patients, 51 received HIDAC prior to the protocol change, and subsequently, 29 received IDAC. The three‐year risk of relapse was significantly higher with IDAC [61%; 95% confidence interval (CI) 40–82] compared with HIDAC (22%; 10–34), P < 0·01. Our findings suggest HIDAC, rather than IDAC, is the preferred dose for single‐agent cytarabine consolidation in young, favourable‐risk AML following 7+3 induction.